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Quantification of CT-assessed radiation-induced lung damage in lung cancer
patients treated with or without chemotherapy and cetuximab
HODA SHARIFI1,5, WOUTER VAN ELMPT1, CARY OBERIJE1, GEORGI NALBANTOV1, MARCO DAS1,2, MICHEL ÖLLERS1,
PHILIPPE LAMBIN1, ANNE-MARIE C. DINGMANS4 & DIRK DE RUYSSCHER1,3
1Department of Radiation Oncology (MAASTRO clinic) GROW, School for Oncology and Developmental Biology, Maastricht University Medical
Center, Maastricht, The Netherlands, 2Department of Radiology, Maastricht University Medical Center, Maastricht, The Netherlands, 3Department
of Radiation Oncology, University Hospitals Leuven/KU Leuven, Belgium, 4Department of Pulmonology, University Medical Center, Maastricht,
The Netherlands, and 5Department of Physics, Oakland University, Rochester, Michigan, MI, USA
ABSTRACT
Background and Purpose: Prediction models for radiation-induced lung damage (RILD) are still
unsatisfactory, with clinical toxicity endpoints that are difficult to quantify objectively. We therefore
evaluated RILD more objectively, quantitatively and on a continuous scale measuring the lung
tissue density changes per voxel.
Material and methods: Patients treated with radiotherapy (RT) alone, sequential and concurrent
chemo-RT with and without the addition of cetuximab were studied. Follow-up computed
tomography (CT) scans were co-registered using deformable registration to baseline CT scans. CT
density changes were correlated to the RT dose delivered in every part of the lungs.
Results: One hundred and seventeen lung cancer patients were included. Mean dose to tumor was
60 Gy (range 45–79.2 Gy). Dose response curves showed a linear increase in the dose region
between 0 and 65 Gy having a slope (based on coefficients of the multilevel model) expressed as a
lung density increase per dose of 0.86 (95% CI 0.73–0.99), 1.31 (95% CI 1.19–1.43), 1.39 (95% CI
1.28–1.50) and 2.07 (95% CI 1.93–2.21) for patients treated only with RT (N¼19), sequential chemo-
RT (N¼30), concurrent chemo-RT (N¼49), and concurrent chemo-RT with cetuximab (N¼19),
respectively.
Conclusions: CT density changes allow quantitative assessment of lung damage after fractionated
RT, giving complementary information to standard used clinical endpoints. Patients receiving
cetuximab showed a significantly larger dose response compared with other treatments.
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Radiotherapy (RT) is a standard treatment in patients with
stage I, II, III, and IV lung cancer [1]. Radiation-induced lung
damage (RILD), i.e. pneumonitis and fibrosis is common in
these patients after RT [2,3]. Radiological findings usually
appear within three months after RT and are progressive
thereafter [4]. Most patients have asymptomatic RILD.
However, RILD has traditionally been scored on clinical
grounds, such as dyspnea or the use of corticoids as reflected
in some scoring systems as CTCAE-RTOG. The drawback of
these clinically relevant scoring systems is their subjectivity, the
fact that these are ordinal scales, the implicit assumption that
each step represents the same functional impairment and
importantly that these endpoints are not specific for radiation
damage. As an example, dyspnea may be related to heart
failure or exacerbation of chronic obstructive lung disease
(COPD) [5,6]. An objective scoring system of RILD on a
continuous scale would be of great value for more reliable
dose-effect relationships could be derived, including genetic
features of the patient [7–9].
It has been shown that radiation-induced local lung density
changes are often detected on follow-up computed tomog-
raphy (CT) scans and can be more objectively quantified. This
approach has been investigated in several studies [2,3,10,11].
Additionally a local dose response curve (DRC) of different
parts of the lungs might be extracted, based on visual
semi-quantitative assessment [12]. However, a CT-based prac-
tical objective quantitative system would greatly be
acknowledged.
Moreover, as locally advanced lung cancer is preferably
treated in a multi-modal (combining chemotherapy with RT or
both chemo-RT and surgery) way, there is a need for methods
that can quantify additional or incremental damage from
combining treatment options including chemotherapy plus RT
and more recently in trials also in combination with the
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monoclonal antibody against the epidermal growth factor
receptor (EGFR) cetuximab [13–15]. Cetuximab, a monoclonal
antibody against the EGFR has shown activity in non-small cell
lung cancer (NSCLC) and in addition it has been found to
potentiate the effects of chemotherapy and RT in experimental
systems [16].
The aim of this study was to use the regional lung tissue
density changes per voxel to evaluate RILD objectively.
Therefore, we compared changes in density measured by CT
imaging over time from four different treatment schedules for
NSCLC and small cell lung cancer (SCLC): RT alone, sequential
chemo-RT, concurrent chemo-RT, and concurrent chemo-RT
with the addition of cetuximab.
Material and methods
Patient characterization and treatment
CT scans of lung cancer patients (both NSCLC and SCLC) were
retrieved for patients receiving radical RT between 2004 and
2010 at MAASTRO clinic. Patients surviving up to six months
from the end of RT that had post-treatment CT scans available
(range 2.5–6 months), were considered in the study. Multiple
treatment regimens of lung cancer were analyzed: RT alone,
sequential and concurrent chemo-RT, concurrent chemo-RT
with the addition of the targeted agent cetuximab, the latter
in a phase I trial NCT00522886 [17]. The follow-up CT scans
were collected from the three referring medical centers in
the region.
The patients were treated with three-dimensional conformal
RT (3DCRT) with an individualized schedule as previously
described [18–20]. Treatment planning was done according to
European Organization for Research and Treatment of Cancer
(EORTC) guidelines [21]. Treatments were planned using XiO RT
planning system (Elekta, Crawley, UK) using a superposition
algorithm with density inhomogeneity corrections. Various
fractionation schedules were used according to clinical proto-
col and cancer type (SCLC or NSCLC). Fractionation for the
SCLC and NSCLC was 1.5 Gy/fraction (twice daily), for the first
45 Gy. The NSCLC were then further escalated up to normal
tissue constraints in daily fractions of 2 Gy up to a maximum of
69 Gy for the concurrent chemo-RT group. For the sequential
chemo RT of NSCLC a 1.8 Gy/fraction (twice daily) was
delivered up to normal tissue constraints to a maximum of
79.2 Gy. Stereotactic body RT patients with high fraction doses
were excluded from the analysis. A radiation oncologist verified
the patients with recurrence as well as patients that had
undergone surgery and these patients were excluded from
the study.
For sequential chemo-RT in NSCLC, three cycles of cisplatin
and gemcitabine were given, followed after 3–4 weeks by RT.
For concurrent chemo-RT in NSCLC, three cycles of cisplatin
and vinorelbine followed by two courses of gemcitabine/
carboplatin were administered. In the framework of a phase I
trial (NCT00522886) in patients with stage III NSCLC, the same
concurrent chemo-RT regimen was combined with concurrent
cetuximab. In SCLC, concurrent chemo-RT was given with
cisplatin and etoposide. SCLC patients received a mean tumor
dose [planning tumor volume (PTV)] of 49.5 Gy (range 45–54
Gy). The NSCLC patients received a mean PTV of 62.9 Gy (range
45–79.2 Gy).
Imaging and follow-up scans
The radiation treatment planning CT scans prior to RT
treatment (pre-RT scans) were used as baseline scans. The
scanner used was a Siemens Biograph 40 PET-CT. CT images
were acquired at 120 kV with a 512 512 image matrix; voxel
size of 0.98 mm 0.98 mm 3 mm and reconstructed using
filtered back projection (FBP). These pre-RT scans used for
treatment planning purposes were mainly non-contrast
enhanced respiratory gated CT scans, whereas the follow-up
CT scans were with contrast typically acquired in breath-hold.
In the contrast enhanced CT scans, the effect of contrast agent
uniformly increases the CT density. In order to account for the
influence of contrast agent on the CT, the offset of these
measurements was normalized to the first dose bin (see next
paragraph). This eliminates the influence of contrast agent on
the measurements [2].
The delineations of the organs at risk and target volumes
were made based on a mid-expiration CT phase of a respiratory
gated CT scan acquired in RT treatment position on a flat table
top of the scanner [22]. Follow-up scans were acquired in the
referring hospital in breath-hold on a diagnostic CT scanner
typically with a curved table top. As the baseline scan and the
follow-up scans were acquired at different breathing phases,
the influence on the lung density was investigated. Mid-
ventilation phase of the 4D-CT scans of four patients were
compared to the breath-hold CT scans acquired post-treatment
in order to quantify possible differences. Post-irradiation (3–6
months) pulmonary fibrosis (radiographic changes) (CTCAE 3.0)
was available for a sub-group of patients that made it possible
to correlate the CT density changes with physician-graded
radiological fibrosis scores.
Image registration and data analysis
To compensate for different patient set-up inside the CT
scanner, breathing state, and small deformations we used non-
rigid image registration to register follow-up scans to baseline
scans. Image registration and deformation was performed
using an in-house Matlab-based tool validated for image
registration inside the thorax [23]. After a rigid registration
step, non-rigid registration was applied to align two images
from the same patient at the two time points. Non-rigid
registration was based on the Morphons algorithm using eight
resolution steps of 10 iterations with a Gaussian smoothing
filters of 1.5 times the voxel dimensions [23]. The algorithm has
been investigated for accuracy of tumor residue by Spijkerman
et al. [24]. For lung tissue registration this method had accuracy
well below 5 mm resampling in which we have used in this
study. Delineations of the lung and the PTV together with the
3D dose distribution were exported from the treatment
planning system. Small errors in registrations at the borders
between the lungs and the ribs could influence the density
measurements; therefore we eroded the lung contours
by 5 mm.
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A volume of interest (e.g. mask) was based on the lung
contours. The dose distribution was split into bins of 1 Gy
ranging from 0 to 70 Gy, the mask was overlaid on the CT
images and the difference in CT density [Hounsfield Units (HU)]
between the pre-RT and follow-up scan was calculated. The
density changes on the lung were considered without the PTV.
In order to account for possible differences in the lung volume,
scanner model and type, and intra-venous contrast media
administration, we normalized (by subtracting) the change in
density in the entire curve to the first dose bin, in accordance
with the study of Boersma et al. [25]. A DRC was generated for
each patient, showing the density change as a function of dose
for these bins. The DRCs of the patients for each treatment
group were combined (i.e. mean) to create population DRCs.
Statistical analysis
We used R (R Core Team, 2012) and lme4 (Bates, Maechler &
Bolker, 2012) to perform a linear mixed effects analysis of the
relationship between density changes and treatment. By using
this type of regression model it is possible to account for the
association that exists between multiple measurements from
the same patient. Likelihood ratio tests were applied to
compare models and a p-value of 50.05 was considered
statistically significant. Radiation dose, systemic treatment and
an interaction term were entered into the model. In addition, a
random intercept was used to obtain a regression line for each
patient, which resulted in a group of parallel regression lines.
Instead of estimating an intercept for each patient, a single
variance parameter was estimated, representing how spread
out the random intercepts were around the common intercept
of each treatment group.
Results
CT scans from 117 lung cancer patients were evaluated; 88% of
the patients had their follow-up scans between 3 and 6 months
after RT, and 12% had their follow-up scans between 2.5 and 3
months after RT.
Multiple treatment regimens of lung cancer were retro-
spectively analyzed: RT alone (N¼19), sequential (N¼30) and
concurrent chemo-RT (N¼49), concurrent chemo-RT with the
addition of the cetuximab (N¼19) (Table I).
For 58 patients, post-irradiation (3–6 months) CTCAE radio-
graphic fibrosis scoring was available. There was a significant
correlation between the mean CT density changes and
physician-graded radiological fibrosis scores 1 (2-test
p¼0.01). Twenty-seven patients showed a fibrosis score of 0,
and 31 of the patients had a fibrosis score 1. For the latter
group of patients, density increase in the lungs was also visible
in the radiological scans, indicating pneumonitis and/or
fibrosis. The difference between different breathing phases
was estimated to be around a mean value of 10 ± 7 HU, mainly
around the edges of the lung contours. This minor difference
was minimized by eroding the lung contour by 5mm after
registration. Density increase in the lung was visually apparent
from the follow-up scans and also resulted in density increase
depending on the dose (Figure 1). The density changes for low
dose regions (regions below 10 Gy) were small (55 HU). CT
density changes for all patient population groups followed an
increasing trend for all doses up to 70 Gy (Figure 2) Scatter-
plots of density changes vs. dose for all treatment groups are
found in Figure 1 of the Supplementary material. The mean
increase in HU and the standard error was 34 ± 11, 39 ± 11,
41 ± 10, and 50 ± 11 for RT, sequential chemo-RT, concurrent
chemo-RT, and concurrent chemo-RT with cetuximab,
respectively.
DRCs were approximately linear in the dose region between
0 and 70 Gy. Using the coefficients of the multilevel model we
estimate a slope expressed as a lung density increase per dose
(HU/Gy), of 0.86 (95% CI 0.73–0.99), 1.31 (95% CI 1.19–1.43),
1.39 (95% CI 1.28–1.50) and 2.07 (95% CI 1.93–2.21) for patients
treated only with RT, sequential chemo-RT, concurrent chemo-
RT, and concurrent chemo-RT with cetuximab, respectively. The
method of Shinichi Nakagawa and Holger Schielzeth [26] was
used to calculate the R2. This method derives two R2 values
which are suitable for using in mixed models. The first is called
the marginal R2 which describes the proportion of variance










Stage I 10 – 2 –
Stage II 3 1 2 –
Stage IIIa – 7 14 8
Stage IIIb 5 20 26 10
Stage IV 1 3 2 1*
Mean PTV dose range(median), [Gy] 45–79 (61) 45–79 (60) 45–69 (55) 55–69 (65)
Mean lung dose range(median), [Gy] 3.9–17.8(9.5) 7.8–21.7(16.9) 3.6–22.0(15.0) 8.2–20.2(17.4)




Tumor type N (%)
NSCLC 96 (82%)
SCLC 21 (18%)
Nicotine use N (%)
Non-smoker 5 (5%)
Current smoker 39 (36%)
Ex-smoker 64 (59%)
Patient characteristics per treatment group. (*stage IV due to Oligometatastic disease).
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explained by the fixed factor(s) alone. The second is the
conditional R2, which describes the proportion of variance
explained by both the fixed and random factors. In this study,
the marginal R2 was 0.22 while the conditional R2 was 0.56.
Results of the linear mixed model showed a linear increase
of density changes as a function of dose for all treatment
groups (Figure 2) Liner mixed model coefficients are shown in
Table 1 of supplementary material. A linear model (with the
variable dose and treatment modality) compared to an
intercept only model resulted in a p-value of 52.2 1014.
Moreover, entering the interaction term of radiation dose and
systemic treatment resulted in a statistically significant
improvement of the model (LR test, p50.001), indicating that
the radiation dose effect on the density changes depended on
the systemic treatment. The DRC was steepest for the group
treated with concurrent chemo-RT with cetuximab as seen in
Figure 2.
The density change of every individual patient, irrespective of
the dose and treatment, is plotted in Figure 3, showing the
patient-specific random intercepts and the 95% confidence
intervals around the patient random intercept. If these intercets
are around zero, it means that there is no variance around the
fixed effect intercept. So in other words, the patient-specific
effect is negligible. The plot shows that there are considerable
differences between patients. The random intercept explains a
large part of the variance in the density. It can be concluded that
individual radiosensitivity differs greatly among patients. A
likelihood ratio for the patient effect (random intercept) was
performed which resulted in an p50.001, indicating that the
variance in the density change explained by the patient variable
is statistically significant. However, although the plot gives an
indication of the differences between patients and the uncer-
tainty surrounding the point estimate, we can not really quantify
this. The random intercept in the model is expressed as the
Figure 1. Example of a patient showing increased lung density in the post-treatment scans inside the irradiated area. The pre-treatment scan and follow-up scan are
shown. The yellow contours represent the planning target volume (PTV). Patient shows a severe change in density. The mean density change is 108 HU. The bottom
plot shows the average increase for the various dose bins for this patient, error-bars represent standard error of the mean (SEM). For illustration purposes, the results
are binned into 10 Gy bins.
Figure 2. The linear mixed model showed a linear increase of density changes as
a function of dose for all treatment groups. The higher increase in density
changes was observed in the group treated with cetuximab.
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amount of variance, there is no coefficient estimated for each
individual patient. Moreover, the distribution in Figure 3 is
comparable to standard errors of fixed effects. As the number of
measurements varies between patients, we can not perform a
formal test for this effect.
Discussion
A majority of patients receiving RT have asymptomatic RILD.
RILD is of importance since it is an important dose limiting
toxicity. Traditional RILD scoring is only based on subjective
clinical scoring systems. This study demonstrates that CT
density measurements allows a quantitative evaluation of RILD
that correlates with physician assigned fibrosis. This method
may be used to identify damage induced by a combination of
radiation and drugs, e.g. adding monoclonal antibodies, such
as cetuximab. Furthermore, CT imaging gives complementary
and more objective information than standard used clinical
endpoints. The imaging endpoint considered in this study is
the HU density change, assessed in radiation dose bins of 1 Gy.
Using the presented multi-level technique used in this study
we could detect the individual susceptibility to RILD for each
patient and also quantify RILD for four different treatment
groups.
The results of our findings were similar to previous studies
showing an increase in density up to a dose of 70 Gy [12,27,28].
As indicated also in the study from Phernambucq et al. there is
significant density increases in 2.5–6 months post-radiation
treatment [29]. A large inter-individual variability was seen in
the severity of lung damage, which was an indication that
patients were affected differently by high doses and may be
due to differences in radiosensitivity [30,31]. This variability was
also seen within each treatment group. Previous studies have
also reported such patient-to-patient variability in normal lung
injury [2,11,32].
A study from van den Heuvel et al. showed that the addition
of cetuximab to concurrent cisplatin increased pulmonary
toxicity [33]. We speculate that cetuximab interferes with
normal tissue repair leading to a more pronounced inflamma-
tory and or fibrotic reaction with unclear clinical consequences.
Boersma et al. and Ma et al. also found increases in CT density
in the low dose (55 Gy) region which led to an offset in the
DRCs [3,25]. Likewise, in our study such differences in the DRCs
were evident. As a result for each patient we normalized our
data to average magnitude of the low dose region (dose
interval of 0–1). These offsets may have resulted from a
number of reasons. It may have been due to differences in
scanner types and scan acquisition protocols, the effect of
contrast, as well as the difference in the lung volume during
the image acquisition of the planning scans (mid-expiration)
and the follow-up scans (breath-hold), which is addressed by a
difference in the CT density.
Deformable registration was necessary in this study since
the scans before and after treatment were not acquired at the
same breathing phase, the same scanning table top, and it also
accounts for different breathing phases. Rigid registration lacks
accuracy for sufficiently comparing the density changes after
RT on a local (e.g. voxel) level [10].
By quantitatively assessing lung damage after different RT
regimens, the radiological changes can be related to the dose
distributions and could serve as an early detection of lung
injury. It can also be a predictive measure of cancer recurrence
at an early time point after treatment as shown also in a study
by Mattonen et al., where CT image texture analysis (ground
glass opacity appearance) of follow-up scans within 5 months
of treatment, demonstrated the ability to predict recurrence
[34]. In their study two of the nine features that were calculated
were the mean CT density and the standard deviation of the CT
density as is discussed in our study [35].
The limitations of our study were that all scans were not
collected throughout a study, therefore some parameters,
including scanner types and scan acquisition protocol were not
matching for all patients. The planning CT scan was used as the
baseline scan because of the availability of all delineated
structures and less variation in the acquisition protocol at
baseline compared to the diagnostic CT scan. Also compara-
tively smaller sample size was available for the group treated
with cetuximab. Another limitation was that fixed follow-up
time points were not available.
This method of analysis paves the way for future studies
that allow objective analysis of lung toxicity that take into
account patient to patient variability observed in the CT
measurements on a local level. Such analysis techniques make
optimal use of the current availability of imaging in routine
practice. CT density changes are only a surrogate for one
aspect of RILD. Although dyspnea is the only relevant symptom
for the patient, it is a multi-factorial, subjective and semi-
quantitative endpoint. CT density changes may allow dissect-
ing the causes of dyspnea after RT to finally come to clinical
interventions.
We implemented a method for generating dose-response
relationships for RILD. Our analyses indicate that there is a
dose-dependent CT density increase for patients receiving RT.
Increase in density changes was to a lesser extent related to
Figure 3. The plot shows the patient-specific random intercepts and the 95%
confidence intervals around the patient random intercept. If these intercepts are
around zero, it means that the density change could be modeled by just using
fixed effects. So, in other words, the patient-specific effect is negligible.
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the systematic treatment and this increase is enhanced for
patients receiving cetuximab in addition to concurrent chemo-
RT. The current analysis technique is an objective and
quantitive method to determine lung damage.
Declaration of interest: The authors report no conflicts of interest. The
authors alone are responsible for the content and writing of the paper.
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